January 2019
Price: £95 PLUS VAT
Format: DOWNLOADABLE PDF
This seminar considered the future role of NICE, its collaboration with NHS England, and the key challenges and developments facing the medtech and pharmaceutical industries.
Delegates at this seminar looked at the challenges and opportunities for NICE in scaling up to provide faster assessments of the clinical and cost-effectiveness of new medicines, following agreement of the Voluntary Scheme for Branded Medicines Pricing and Access, which includes plans to provide NHS funding for those medicines recommended by NICE.
Attendees also discussed the practicalities of implementing further potential changes to the appraisal process following the Department of Health and Social Care’s decision to charge companies for technology appraisals, including the decision to provide smaller companies with a partial exemption, and implications for NICE’s budget and to patient access.
Further sessions assessed future priorities for NICE in adapting to changes across the health and social care landscape - including on using data and reducing variation - and priorities for developing future guidelines, with discussion on the role of NICE in supporting shared decision making, evidence-based decommissioning and clinical excellence.
